Metacrine, Inc. Common Stock
MTCR
MTCR was delisted on the 8th of February, 2023.
31 hedge funds and large institutions have $3.83M invested in Metacrine, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
72% more capital invested
Capital invested by funds: $2.23M → $3.83M (+$1.61M)
7.11% more ownership
Funds ownership: 7.86% → 14.97% (+7.1%)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$1.54M |
| 2 |
Bank of New York Mellon
New York
|
+$109K |
| 3 |
Renaissance Technologies
New York
|
+$102K |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
+$84.2K |
| 5 |
Two Sigma Advisers
New York
|
+$17.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$102K |
| 2 |
VF
Virtu Financial
New York
|
-$82K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$56K |
| 4 |
EGM
Engineers Gate Manager
New York
|
-$55K |
| 5 |
Millennium Management
New York
|
-$48K |
MTCR Hedge Fund Activity: Q1 2022 in Review
31 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q1 2022, worth a combined $3.83M — up 72% from $2.23M a quarter earlier.
Fund positioning in MTCR was balanced in Q1 2022: 8 funds opened new positions, 8 closed out, 12 added to existing stakes and 4 trimmed.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $1.54M. The largest seller was Goldman Sachs, cutting an estimated $102K.
- 31 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $3.83M of Metacrine, Inc. Common Stock stock for Q1 2022, up 72% quarter-over-quarter.
- 8 funds opened new Metacrine, Inc. Common Stock positions in Q1 2022 and 8 closed out, a net change of 0 holders.
- The largest Metacrine, Inc. Common Stock buyer in Q1 2022 was Arch Venture Management, an estimated $1.54M added.
- The largest Metacrine, Inc. Common Stock seller in Q1 2022 was Goldman Sachs, an estimated $102K sold.
Based on aggregated 13F filings for Q1 2022.